Forging ACO Partnerships Align ACO and Institutional Sales Strategies for National Product Success 9 - 10 December 2014 | Philadelphia, PA
14th Bio/Pharma Contact Centers Conference Optimize Contact Center and Patient Service Effectiveness Amid Increasing Regulations, Specialty Products and Social Media Channels 21 - 22 January 2015 | Philadelphia, PA
Social Media in the Pharmaceutical Industry Reflecting on regulatory insights, customer focus, mobile & website advances and the vision for the industry in 2015 21 - 22 January 2015 | Marriott Regents Park Hotel, London, UK
PCC 2015 - CBI's 12th Annual Pharmaceutical Compliance Congress Widely recognized as the most comprehensive, senior-level compliance meeting, CBI's esteemed Pharmaceutical Compliance Congress (PCC) attracts more than 400 industry leaders, including dozens of CCOs and their legal, compliance and regulatory teams. 27 - 28 January 2015 | Washington, DC
Big Data in Pharma Europe Taking the Next Steps on the Big Data Journey to Revolutionise Value-Based Personalised Healthcare 27 - 29 January 2015 | London, UK
Selected Content from Recent Issues of Pharma Marketing News
A Formula for Patient-Centric mHealth Apps
Eliminating the Hurdles to Developing High Quality Pharma Mobile Health Apps
Why haven't the top pharma companies, which are so successful in marketing their products, achieved success as leading mHealth app publishers? What stands in the way of pharma developing high quality mobile health apps? To answer those questions, Pharmaguy and the Mobile Health Competence Centre in Barcelona sponsored a "debate" within the LinkedIn Mobile Health Group and a #mHealthPharma TweetChat.
This article summarizes the comments from that debate and TweetChat and condenses the learnings into one simple formula for creating quality pharma mHealth apps.
Correcting Independent 3rd-Party "Misinformation" About Prescription Drugs
Eliminate the "Influence Prong," Says Pharma Industry
It took the FDA more than four and one-half years to finally issue two social media guidance documents in June, 2014, that addressed the major issues discussed at the 2009 public hearing hearing on regulating the "Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools."
This article summarizes the industry's response to the second guidance document regarding correcting and/or responding to misinformation related to a firm's own FDA-approved products when that information is created or disseminated by independent third parties on the Internet or through social media.
Topics include (partial list):
What is "Misinformation?"
The Influence Prong
What is UGC?
Don't Chill Our Speech, Dude!
Wikipedia's "Bright Line Rule"
Hiring Agents to Make Edits
Chart: A Process for Correcting Wikipedia Information